Accretion Nutraveda shareholders approve MOA amendments expanding business scope
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Microcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shareholders approved amendments to the Memorandum of Association via postal ballot on October 9, 2026. Main Object Clause expanded to cover nutraceuticals, pharmaceuticals, Ayurvedic, Homeopathic and Allopathic medicines, cosmetics, medical devices, hospitals, diagnostic centres and CROs. New sub-clauses 58-69 added covering investments, agriculture, farming, backward-forward integration and research labs. This significantly widens the company's permitted business activities.
Signals potential diversification beyond nutraceuticals into pharma, healthcare, agriculture and food sectors. Watch for new business plans.